Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence

Participants will complete a patient-reported outcome measure for their oral anticancer agent at two timepoints over 2 months, to assess patient symptoms and adherence to their oral anticancer agent.

Following the first patient-reported outcome measure, participants will be contacted by the community pharmacist for a Comprehensive Medication Review (CMR) for their chronic medications. A follow-up CMR will take place after the second patient-reported outcome measure.

Throughout the study, the oncology and community pharmacists will communicate about medications through the electronic medical record.